Convergence Investment Partners’s AstraZeneca AZN Stock Holding History

Convergence Investment Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-274	Closed	-$19K	–	355
2018 Q1	$19K	Buy	+274	New	+$19K	﹤0.01%	602
2015 Q1	–	Sell	-2,967	Closed	-$209K	–	362
2014 Q4	$209K	Sell	2,967 -77	-3%	-$5.51K	0.03%	336
2014 Q3	$217K	Buy	+3,044	New	+$223K	0.03%	336
2014 Q2	–	Sell	-3,786	Closed	-$246K	–	370
2014 Q1	$246K	Sell	3,786 -1,081	-22%	-$69.8K	0.04%	324
2013 Q4	$289K	Sell	4,867 -784	-14%	-$42.6K	0.05%	315
2013 Q3	$293K	Sell	5,651 -1,591	-22%	-$79.9K	0.06%	244
2013 Q2	$343K	Buy	+7,242	New	+$369K	0.09%	240

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Convergence Investment Partners's AZN Position: Q2 2018 in Review

Convergence Investment Partners sold out of AstraZeneca (AZN) in Q2 2018, closing a stake of 274 shares — an estimated $19K sold.

Convergence Investment Partners first reported a position in AZN in Q2 2013 and held it in 7 quarters. The position peaked at $343K in Q2 2013. 530 funds tracked by Wall St. Rank hold AZN as of Q2 2018.

Convergence Investment Partners reported no remaining AstraZeneca position as of Q2 2018 after selling out during the quarter.
Convergence Investment Partners sold 274 AstraZeneca shares in Q2 2018, an estimated $19K.
Convergence Investment Partners first reported a position in AstraZeneca in Q2 2013 and held it in 7 quarters.
Convergence Investment Partners's AstraZeneca position peaked at $343K in Q2 2013.
530 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2018.

Based on Convergence Investment Partners's 13F filing for Q2 2018, filed 7 Aug 2018.